<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255238</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GLCL001</org_study_id>
    <nct_id>NCT04255238</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Compared to add-on Therapy With Gemigliptin 50 mg in Combination With Metformin or Dapagliflozin 10 mg in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of dual add-on therapy&#xD;
      with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy&#xD;
      with Gemigliptin 50 mg in combination with Metformin or Dapagliflozin 10 mg in combination&#xD;
      with Metformin in patients with type 2 diabetes mellitus who have inadequate glycemic control&#xD;
      on metformin alone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chages from baseline HbA1c at Week24</measure>
    <time_frame>Baseline to Week24</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">468</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Gemigliptin 50 mg and Dapagliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin 10 mg per day&#xD;
Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemigliptin 50 mg and Dapagliflozin placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin placebo per day&#xD;
Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemigliptin placebo and Dapagliflozin 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject shoud took 1 tablet of Gemigliptin placebo and 1 tablet of Dapagliflozin 10 mg per day&#xD;
Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin 50mg</intervention_name>
    <description>The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day</description>
    <arm_group_label>Gemigliptin 50 mg and Dapagliflozin 10 mg</arm_group_label>
    <arm_group_label>Gemigliptin 50 mg and Dapagliflozin placebo</arm_group_label>
    <other_name>Zemiglo tab 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day</description>
    <arm_group_label>Gemigliptin 50 mg and Dapagliflozin 10 mg</arm_group_label>
    <arm_group_label>Gemigliptin placebo and Dapagliflozin 10mg</arm_group_label>
    <other_name>Forxiga tab 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes mellitus&#xD;
&#xD;
          -  Patients upper 19 years old&#xD;
&#xD;
          -  Patients who had taken Metformin(≥1000mg/day) more than 8 weeks and who have&#xD;
             inadequate blood glucose control&#xD;
&#xD;
          -  Patients who have signed an informed consent themselves after receiving explanation&#xD;
             about the clinical study&#xD;
&#xD;
          -  Patients who are applicable to one of the three in the following.&#xD;
&#xD;
               1. Surgically infertile patients&#xD;
&#xD;
               2. Postmenopausal female patients of ≥45 years of age for whom ≥2 years elapsed&#xD;
                  since their last menstruation&#xD;
&#xD;
               3. Premenopausal fertile female patients or surgically non-infertile male patients&#xD;
                  who have agreed to use at least 2 kinds of contraceptive measures (certainly&#xD;
                  including one of the barrier methods) to avoid pregnancy until 14 days after the&#xD;
                  last dose of the investigational product&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 diabetes mellitus, Diabetic ketoacidosis, Metabolic acidosis&#xD;
             Diabetic coma, Diabetic pre-coma&#xD;
&#xD;
          -  Patients with Gestational diabetes, or secondary diabetes&#xD;
&#xD;
          -  Patients with NYHA Class II~IV congestive heart failure or arrhythmia requiring&#xD;
             treatment&#xD;
&#xD;
          -  Patients whose TSH level is out of the normal range and who have thyroidal dysfunction&#xD;
             requiring drug therapy&#xD;
&#xD;
          -  Patients with positive Serologic results of HBsAg, HCV Ab, HIV Ab test within 4 weeks&#xD;
             prior to Visit 1 (Screening) or at Visit 1 (Screening)&#xD;
&#xD;
          -  Patients with Body Mass Index(BMI) #40 kg/m2&#xD;
&#xD;
          -  Patients who are receiving intravenous iodine contrast agents within 48 hours prior to&#xD;
             Visit 1(Screening) or planned during the clinical trial period (eg, intravenous&#xD;
             urography, venous cholangiography, angiography, computed tomography using contrast&#xD;
             media, etc.).&#xD;
&#xD;
          -  Patients with pulmonary embolism, severe pulmonary dysfunction, or who are susceptible&#xD;
             to be accompanied by hypoxemia at the time of Visit 1(Screening)&#xD;
&#xD;
          -  Patients on clinically significant dehydration, diarrhea, and vomiting at the time of&#xD;
             Visit 1(Screening)&#xD;
&#xD;
          -  Patients with pituitary insufficiency or adrenal insufficiency at the time of Visit&#xD;
             1(Screening)&#xD;
&#xD;
          -  Patients with a history of alcoholism or drug addiction within 1 years prior to Visit&#xD;
             1(Screening)&#xD;
&#xD;
          -  Patients with a history of malignant tumors within 5 years prior to Visit&#xD;
             1(Screening). However, patients with basal cell or squamous cell skin cancer, or in&#xD;
             situ cervical cancer treated properly can participate in the study.&#xD;
&#xD;
          -  Patients with the outcomes of the laboratory tests performed at Visit&#xD;
&#xD;
             1(Screening) applicable to the criteria below&#xD;
&#xD;
               -  Bilirubin &gt;2 × upper limit of normal(ULN)&#xD;
&#xD;
               -  AST/ALT &gt;3 × ULN&#xD;
&#xD;
          -  Patients with a history of hypersensitivity reactions to the drugs below&#xD;
&#xD;
               -  Dipeptidyl-peptidase4(DPP4) inhibitors&#xD;
&#xD;
               -  Sodium/glucose co transport-2(SGLT-2) inhibitor&#xD;
&#xD;
               -  Biguanides&#xD;
&#xD;
          -  Patients who were administered the drugs below&#xD;
&#xD;
          -  Patients who had been administered anti-obesity drugs within 12 weeks prior to Visit&#xD;
             1(Screening)&#xD;
&#xD;
          -  Patients who have undergone bariatric surgery within the 1 year prior to Visit 1&#xD;
             (Screening) or are scheduled during the trial&#xD;
&#xD;
          -  Patients with a genetic problems such as Galactose intolerance, Lapp lactose&#xD;
             deficiency, Glucose-galactose malabsorption)&#xD;
&#xD;
          -  Female patients who are pregnant or lactating&#xD;
&#xD;
          -  Patients who have an experience of participation in another clinical study within 12&#xD;
             weeks prior to Visit1(screening)&#xD;
&#xD;
          -  Patients who are otherwise considered to be ineligible for this study on&#xD;
             investigators' judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eunjoo Cho</last_name>
    <phone>+82-2-6987-4284</phone>
    <email>eunjoo.cho@lgchem.com</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

